GPC Satraplatin Prostate Cancer Rolling NDA To Complete In Second Half Of 2006
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm seeks second-line indication for the oral platinum compound following completion of accrual in pivotal SPARC trial.
You may also be interested in...
GPC Aims To Complete Satraplatin NDA In January, Despite Arbitration With Licensor Spectrum
Spectrum is seeking $12 million GPC was paid by sublicensee Pharmion.
GPC Aims To Complete Satraplatin NDA In January, Despite Arbitration With Licensor Spectrum
Spectrum is seeking $12 million GPC was paid by sublicensee Pharmion.
Pharmion Boosts Oncology Pipeline With Cabrellis Acquisition
Purchase gives Pharmion North American and EU rights to the novel anthracycline amrubicin, currently marketed in Japan for both small and non-small cell lung cancers.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: